S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(0.28%) $78.33
Gas
(0.19%) $2.15
Gold
(0.45%) $2 319.10
Silver
(1.74%) $27.16
Platinum
(-0.48%) $960.70
USD/EUR
(0.02%) $0.929
USD/NOK
(-0.04%) $10.87
USD/GBP
(0.00%) $0.797
USD/RUB
(0.00%) $91.45

实时更新: RenovoRx, Inc. [RNXT]

交易所: NASDAQ 部门: Healthcare 工业: Biotechnology
最后更新时间4 May 2024 @ 04:00

-3.94% $ 1.220

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer...

Stats
今日成交量 23 507.00
平均成交量 38 414.00
市值 29.22M
EPS $0 ( 2024-03-28 )
下一个收益日期 ( $-0.140 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.230
ATR14 $0.0180 (1.46%)
Insider Trading
Date Person Action Amount type
2024-03-06 Gentry Leesa Buy 190 000 Options
2023-06-01 Gentry Leesa Sell 62 500 Options
2024-01-19 Gentry Leesa Sell 60 159 Options
2024-02-09 Kocak Ron Buy 15 000 Options
2022-08-18 Kocak Ron Sell 34 390 Options
INSIDER POWER
70.96
Last 81 transactions
Buy: 2 293 038 | Sell: 2 003 949

RenovoRx, Inc. 相关性

10 最正相关
ALTR0.934
DUOL0.93
OVLY0.925
SVFAU0.921
BIOT0.92
APXI0.918
RAM0.917
ANSS0.916
LCAA0.914
OTEC0.913
10 最负相关
CBNK-0.923
GOOD-0.917
BWB-0.916
GSMG-0.915
ALRS-0.911
CSSEP-0.909
AROW-0.909
GNTY-0.908
FGBI-0.906
JAGX-0.905

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

RenovoRx, Inc. 财务报表

Annual 2023
营收: $0
毛利润: $0 (0.00 %)
EPS: $-0.990
FY 2023
营收: $0
毛利润: $0 (0.00 %)
EPS: $-0.990
FY 2022
营收: $0
毛利润: $-6 000.00 (0.00 %)
EPS: $-1.080
FY 2021
营收: $0.00
毛利润: $0.00 (0.00 %)
EPS: $-0.754

Financial Reports:

No articles found.

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。